Published in Int J STD AIDS on November 01, 2005
Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol (2008) 2.27
Street policing, injecting drug use and harm reduction in a Russian city: a qualitative study of police perspectives. J Urban Health (2006) 1.74
Male sex workers in Moscow, Russia: a pilot study of demographics, substance use patterns, and prevalence of HIV-1 and sexually transmitted infections. AIDS Care (2010) 1.37
Exploring the impact of underage sex work among female sex workers in two Mexico-US border cities. AIDS Behav (2012) 1.32
Hepatitis C virus infection among drug injectors in St Petersburg, Russia: social and molecular epidemiology of an endemic infection. Addiction (2009) 1.27
Toward a comprehensive approach to HIV prevention for people who use drugs. J Acquir Immune Defic Syndr (2010) 0.94
Correlates of unsafe equipment sharing among injecting drug users in St. Petersburg, Russia. Eur Addict Res (2009) 0.93
Capacity enhancement of hepatitis C virus treatment through integrated, community-based care. Can J Gastroenterol (2008) 0.92
Hepatitis C virus seroprevalence among people who inject drugs and factors associated with infection in eight Russian cities. BMC Infect Dis (2014) 0.86
Characteristics of HIV-infected women and factors associated with HCV seropositivity in the Republic of Georgia. AIDS Res Ther (2011) 0.84
Moderate/heavy alcohol use and HCV infection among injection drug users in two Russian cities. Drug Alcohol Depend (2013) 0.77
Impact of incarceration experiences on reported HIV status and associated risk behaviours and disease comorbidities. Eur J Public Health (2015) 0.75
Immune complexes that contain HIV antigens activate peripheral blood T cells. Dokl Biol Sci (2016) 0.75
Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet (2008) 11.44
HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet (2010) 8.02
Global overview of injecting drug use and HIV infection among injecting drug users. AIDS (2004) 5.45
How ideology shapes the evidence and the policy: what do we know about cannabis use and what should we do? Addiction (2010) 5.08
Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ (2010) 3.59
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Situational factors influencing drug injecting, risk reduction and syringe exchange in Togliatti City, Russian Federation: a qualitative study of micro risk environment. Soc Sci Med (2003) 3.56
Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ (2012) 3.46
Injection drug use, commercial sex work, and the HIV/STI epidemic in the Russian Federation. Sex Transm Dis (2003) 3.20
The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction (2011) 2.95
Police violence and sexual risk among female and transvestite sex workers in Serbia: qualitative study. BMJ (2008) 2.91
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (2013) 2.76
Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction (2010) 2.59
Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis (2010) 2.56
Methods to recruit hard-to-reach groups: comparing two chain referral sampling methods of recruiting injecting drug users across nine studies in Russia and Estonia. J Urban Health (2006) 2.52
Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: a multi-city study. Addiction (2006) 2.46
Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction (2012) 2.45
Explosive spread and high prevalence of HIV infection among injecting drug users in Togliatti City, Russia. AIDS (2002) 2.40
Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28
Exploring barriers to 'respondent driven sampling' in sex worker and drug-injecting sex worker populations in Eastern Europe. J Urban Health (2006) 2.17
HIV incidence appears constant in men who have sex with men despite widespread use of effective antiretroviral therapy. AIDS (2004) 2.15
Inequalities in the uptake of human papillomavirus vaccination: a systematic review and meta-analysis. Int J Epidemiol (2013) 2.08
Public injecting and the need for 'safer environment interventions' in the reduction of drug-related harm. Addiction (2006) 2.06
Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ (2004) 2.03
Drug-related mortality and its impact on adult mortality in eight European countries. Eur J Public Health (2005) 2.01
Access and coverage of needle and syringe programmes (NSP) in Central and Eastern Europe and Central Asia. Addiction (2007) 1.95
Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine (2013) 1.94
Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet (2011) 1.90
Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. Making it happen. The WHO strategy" ("3 by 5"). Addiction (2006) 1.87
Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. J Med Virol (2003) 1.84
Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach. AIDS (2010) 1.82
Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction (2007) 1.81
Association between availability of heroin and methadone and fatal poisoning in England and Wales 1993-2004. Int J Epidemiol (2006) 1.78
Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland. J Acquir Immune Defic Syndr (2008) 1.75
Street policing, injecting drug use and harm reduction in a Russian city: a qualitative study of police perspectives. J Urban Health (2006) 1.74
Do tests devised to detect recent HIV-1 infection provide reliable estimates of incidence in Africa? J Acquir Immune Defic Syndr (2007) 1.68
Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology (2011) 1.67
Adolescent alcohol and tobacco use and early socioeconomic position: the ALSPAC birth cohort. Pediatrics (2011) 1.60
Estimating long-term trends in the incidence and prevalence of opiate use/injecting drug use and the number of former users: back-calculation methods and opiate overdose deaths. Am J Epidemiol (2004) 1.57
Childhood conduct disorder trajectories, prior risk factors and cannabis use at age 16: birth cohort study. Addiction (2013) 1.56
Effects of sex work on the prevalence of syphilis among injection drug users in 3 Russian cities. Am J Public Health (2006) 1.54
Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol (2011) 1.50
Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS (2009) 1.49
HIV among people who inject drugs in Central and Eastern Europe and Central Asia: a systematic review with implications for policy. BMJ Open (2012) 1.49
High-prevalence and high-estimated incidence of HIV infection among new injecting drug users in Estonia: need for large scale prevention programs. J Public Health (Oxf) (2008) 1.44
Trends in deaths related to drug misuse in England and Wales, 1993-2004. Health Stat Q (2006) 1.43
Outcomes after viral load rebound on fi rst-line antiretroviraltreatment in children with HIV in the UK and Ireland:an observational cohort study. Lancet HIV (2015) 1.42
Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males. J Med Virol (2011) 1.39
Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis (2013) 1.38
Intrauterine exposure to alcohol and tobacco use and childhood IQ: findings from a parental-offspring comparison within the Avon Longitudinal Study of Parents and Children. Pediatr Res (2008) 1.38
Injecting equipment sharing among injecting drug users in Togliatti City, Russian Federation: maximizing the protective effects of syringe distribution. J Acquir Immune Defic Syndr (2004) 1.37
Prevalence and circumstances of opiate overdose among injection drug users in the Russian Federation. J Urban Health (2003) 1.34
Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med J Aust (2012) 1.33
Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol (2011) 1.32
Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty. Addiction (2004) 1.31
Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis. BMC Public Health (2014) 1.30
Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis. Addiction (2009) 1.30
High HIV prevalence among injecting drug users in Estonia: implications for understanding the risk environment. AIDS (2006) 1.30
Drug-related mortality and fatal overdose risk: pilot cohort study of heroin users recruited from specialist drug treatment sites in London. J Urban Health (2003) 1.29
Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS (2013) 1.28
Access to syringes in three Russian cities: implications for syringe distribution and coverage. Int J Drug Policy (2008) 1.27
Surveillance of HIV-1 subtypes among heterosexuals in England and Wales, 1997-2000. J Acquir Immune Defic Syndr (2004) 1.25
Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services. AIDS Patient Care STDS (2009) 1.23
Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England. BMC Infect Dis (2008) 1.23
Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol (2013) 1.23
Socio-economic status in childhood and later alcohol use: a systematic review. Addiction (2007) 1.21
Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. Eur J Public Health (2011) 1.20
Is socioeconomic status in early life associated with drug use? A systematic review of the evidence. Drug Alcohol Rev (2009) 1.16
A tale of three cities: persisting high HIV prevalence, risk behaviour and undiagnosed infection in community samples of men who have sex with men. Sex Transm Infect (2007) 1.16
Prevalence of personality disorder in alcohol and drug services and associated comorbidity. Addiction (2004) 1.15
Model projections on the required coverage of syringe distribution to prevent HIV epidemics among injecting drug users. J Acquir Immune Defic Syndr (2006) 1.15
Parental drug use, early adversities, later childhood problems and children's use of tobacco and alcohol at age 10: birth cohort study. Addiction (2008) 1.14
Impact of gender and sex work on sexual and injecting risk behaviors and their association with HIV positivity among injecting drug users in an HIV epidemic in Togliatti City, Russian Federation. Sex Transm Dis (2005) 1.14
Examining inequalities in the uptake of the school-based HPV vaccination programme in England: a retrospective cohort study. J Public Health (Oxf) (2013) 1.13
Obstacles in provision of anti-retroviral treatment to drug users in Central and Eastern Europe and Central Asia: a regional overview. Int J Drug Policy (2007) 1.12
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med (2010) 1.12
Low incidence of hepatitis C virus among prisoners in Scotland. Addiction (2013) 1.11
Characterizing patterns of smoking initiation in adolescence: comparison of methods for dealing with missing data. Nicotine Tob Res (2011) 1.06
The prevalence of injecting drug use in a Russian city: implications for harm reduction and coverage. Addiction (2004) 1.05
Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. J Viral Hepat (2007) 1.05
Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere. Drug Alcohol Depend (2010) 1.04
Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission? Drug Alcohol Depend (2013) 1.03
Establishing the Melbourne Injecting Drug User Cohort Study (MIX): rationale, methods, and baseline and twelve-month follow-up results. Harm Reduct J (2013) 1.02
Patterns of alcohol use in early adolescence predict problem use at age 16. Alcohol Alcohol (2012) 1.02
Drug injecting and syringe use in the HIV risk environment of Russian penitentiary institutions: Qualitative study. Addiction (2006) 1.01